Why does the Northstar circulating tumor DNA (ctDNA) show a 20‑fold increase five weeks after microwave ablation of two liver metastases (3.4 cm and 1.1 cm) from a pancreatic neuroendocrine tumor (pNET)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Why ctDNA Increases After Microwave Ablation of pNET Liver Metastases

The 20-fold increase in ctDNA five weeks after microwave ablation most likely reflects massive tumor cell death and DNA release from the ablated lesions, rather than disease progression—this is a well-recognized phenomenon following thermal ablation procedures.

Mechanism of Post-Ablation ctDNA Elevation

Tumor Cell Lysis and DNA Release

When microwave ablation destroys tumor tissue, it causes:

  • Immediate necrosis of tumor cells within and around the ablation zone
  • Massive release of intracellular contents, including tumor DNA, into the bloodstream
  • Disruption of tumor vasculature, facilitating DNA entry into circulation
  • Inflammatory response that may further mobilize tumor-derived material

The ablation of two lesions (3.4 cm and 1.1 cm) represents substantial tumor volume—approximately 20-30 mL of tissue undergoing simultaneous necrosis, which explains the dramatic ctDNA surge.

Temporal Pattern

The 5-week timepoint is consistent with:

  • Peak release period following thermal ablation, as necrotic tissue continues to break down
  • Delayed clearance of DNA fragments from circulation
  • Ongoing inflammatory processes at the ablation sites

This is distinct from progressive disease, which typically shows gradual ctDNA increases over months rather than acute spikes 1.

Distinguishing Treatment Effect from Progression

Key Clinical Considerations

This ctDNA elevation should NOT be immediately interpreted as treatment failure. To differentiate between ablation-related release versus true progression:

  • Obtain follow-up imaging at 6-8 weeks post-ablation using CT or MRI to assess:

    • Ablation zone characteristics (should show expected post-ablation changes)
    • Absence of new lesions
    • No enlargement of existing untreated lesions

  • Serial ctDNA monitoring over the next 8-12 weeks:

    • Expected pattern: ctDNA should decline if ablation was successful
    • Progressive disease pattern: ctDNA remains elevated or continues rising 2, 3

  • Correlation with tumor markers: Check chromogranin A and other relevant markers—these should decrease if ablation was effective 4

Evidence from Ablation Studies

Thermal ablation (RFA/MWA) in neuroendocrine liver metastases demonstrates:

  • 88% of procedures prolong progression-free survival when used for oligoprogression
  • Median PFS of 62.6 weeks after successful ablation
  • Local control rates are excellent with only 6% local recurrence for neuroendocrine metastases (much lower than colorectal metastases at 34%) 5

Clinical Management Algorithm

Immediate Actions (Weeks 5-8 Post-Ablation)

  1. Do NOT escalate systemic therapy based solely on ctDNA elevation at 5 weeks
  2. Obtain contrast-enhanced CT or MRI to assess ablation zones and exclude new disease
  3. Measure tumor markers (chromogranin A, specific hormones if functional tumor)
  4. Repeat ctDNA testing in 4-6 weeks to establish trend

Interpretation Framework (Weeks 8-12)

Successful ablation pattern:

  • ctDNA declining from peak
  • Imaging shows appropriate ablation zones without viable tumor
  • Tumor markers decreasing or stable
  • Action: Continue current surveillance schedule 4

Concerning pattern suggesting progression:

  • ctDNA remains elevated or rising
  • New lesions on imaging or enlargement of existing lesions
  • Rising tumor markers
  • Action: Consider systemic therapy escalation (everolimus, sunitinib, or chemotherapy per guidelines) 4

Important Caveats

Limitations of ctDNA in pNETs

  • Detection rates vary by disease burden: ctDNA is detected in only 66% of metastatic pancreatic neuroendocrine cases 1
  • Liver metastases correlate strongly with ctDNA positivity: Your patient with liver lesions is more likely to have detectable ctDNA 2, 3
  • Tumor volume matters: The correlation between ctDNA quantity and tumor volume is moderate (Spearman's ρ = 0.353-0.500), meaning ctDNA doesn't always perfectly reflect disease burden 2, 3

Common Pitfall to Avoid

Do not interpret post-ablation ctDNA spikes as immediate treatment failure. This is analogous to "tumor flare" seen with other local therapies. The key is establishing the trajectory over 8-12 weeks, not the absolute value at a single timepoint.

Surveillance Strategy Going Forward

Following NCCN guidelines for metastatic pNETs 4:

  • Imaging every 3-6 months with CT/MRI
  • Tumor markers every 3-6 months
  • Consider ctDNA as adjunctive monitoring but not as sole determinant of treatment decisions
  • Additional ablation may be feasible if isolated progression occurs, potentially delaying systemic therapy escalation by up to 123 weeks 5

The 10-year overall survival for patients with resected/ablated neuroendocrine liver metastases is 50.4%, supporting aggressive local therapy approaches 4.

References

4
Guideline

neuroendocrine tumors.

Journal of the National Comprehensive Cancer Network : JNCCN, 2012

Related Questions

What does a 20‑fold rise in the Northstar circulating tumor DNA assay indicate in a patient with a grade 2 neuroendocrine tumor five weeks after microwave ablation?
What does peripheral enhancement on MRI of a pancreatic neuroendocrine tumor liver metastasis treated with microwave (MW) ablation indicate, particularly when one lesion shows restricted diffusion and the other does not?
In a patient with a known well‑differentiated neuroendocrine tumor who underwent microwave ablation of hepatic lesions, are heterogeneous, peripherally enhancing lesions in hepatic segments VII and V on a scan performed two months later consistent with expected post‑ablation changes or indicative of residual/metastatic disease?
Why does a grade‑2 pancreatic neuroendocrine tumor with liver metastases that progressed despite lanreotide and required ablation, despite now having no evidence of disease, indicate a poor prognosis?
After 40 days of oral iron therapy, the patient’s repeat hemoglobin remains low (~106 g/L) and red blood cell indices are decreased; what laboratory and diagnostic studies should be requested?
What is the risk of malignancy for gallbladder polyps?
When is intravenous vancomycin indicated and what is the appropriate dosing regimen?
Should I add a total iron‑binding capacity (TIBC) measurement to the work‑up for a patient on oral iron for 40 days with hemoglobin around 106 g/L and low red‑cell indices?
How can the likelihood of local anesthetic systemic toxicity (LAST) be reduced during dental procedures?
Which symptoms of diarrhea-predominant irritable bowel syndrome (IBS-D) improve with eloxadoline?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.